CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

Additional Metadata
Persistent URL	doi.org/10.1186/1471-2407-10-247, hdl.handle.net/1765/81766
Journal	BMC Cancer
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Dietrich, D., Krispin, M., Dietrich, J., Fassbender, A., Lewin, J., Harbeck, N., … Martens, J. (2010). CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients. BMC Cancer, 10. doi:10.1186/1471-2407-10-247

Publication